Excessive sleep associated with longer time to return to work among colorectal cancer survivors
the ONA take:
Excessive sleep was associated with a longer time to return to work, a reduction in work time, and increased likelihood to retire among colorectal cancer survivors, according to a recent study published online ahead of print in the journal Supportive Care in Cancer.
For the study, researchers in Australia enrolled 239 colorectal cancer survivors in order to assess associations of health behaviors with return to work outcomes following a colorectal cancer diagnosis among men and women aged 45 to 64 years. Participants were interviewed via telephone and answered questionnaires at 6 and 12 months following diagnosis.
Results showed that participants who reported sleeping 9 or more hours per day were 2.69 times more likely to decrease work time or retire compared with those who slept between 7 and 9 hours per day. Researchers found that excessive sleep was also associated with a longer time to returning to work.
The findings suggest that interventions designed to help colorectal cancer survivors achieve optimal sleep may help them return to work sooner. Further studies are warranted to test those interventions.
Excessive sleep was associated with a longer time to return to work, a reduction in work time, and increased likelihood to retire.
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- Breast Conservation Improves Survival vs Mastectomy in Breast Cancer
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|